The ActoBiotics® technology provides a new class of therapeutic agent, a unique delivery platform precisely tailored for specific disease modification, with the potential for superior efficacy and safety via local delivery directly to the relevant tissue.

ActoBiotics® combine the advantages of highly selective protein-based therapeutic agents with local delivery by the well-characterized, safe food-grade bacterium Lactococcus lactis, to provide novel disease-modifying therapies. ActoBiotics® have the potential to provide superior safety and efficacy via the sustained release of appropriate quantities of select therapeutic agents, while reducing the side-effects commonly attributed to systemic delivery and the corresponding peaks in concentration. ActoBio Therapeutics™ has shown that multiple therapeutic agents, such as proteins, peptides and antibodies, can be incorporated into a single approach, enabling the simultaneous targeting of multiple pathways in one disease.

Incorporating validated therapeutic agents into the ActoBiotics® delivery system accelerates the development and regulatory path. This approach facilitates the design and production of novel, specific biological interventions across a range of diseases. With a well-established production process, which is straightforward and easily scalable, ActoBio Therapeutics™ already has two clinical stage programs, and multiple additional programs close to clinical stage.

Some of the significant competitive advantages of ActoBiotics® include:

Specifically designed & genetically engineered

 

Rapid and smart development of new candidates

Targeted delivery

Safety

Scalable manufacturing

Our versatile technology platform, which was developed in-house, has facilitated the creation of diverse ActoBiotics® candidates. Choosing only the most promising leads, we have developed a rich pipeline of therapeutic agents at clinical, preclinical and discovery stage.

At ActoBio Therapeutics™ we focus primarily on the development of products in areas with high unmet needs in immunotherapy, as well as allergy and immune tolerance induction. In addition to these focus areas, we also collaborate with external partners on a number of other programs.

ACTOBIO FOCUS PROJECTS

Immune and inflammation related products being developed in-house

IMMUNOTHERAPY

Oral Mucositis (OM)
Inflammatory Bowel Disease (IBD)
Chronic Rhinosinusitis (CRS)

DESENSITIZATION

Food, seasonal, perennial and venom allergy

TOLERANCE INDUCTION

Type 1 Diabetes (T1D)
Celiac Disease
ACTOBIOTICS®
targeted & designed
microbe-based
pharmaceutical agents

EARLY STAGE PROGRAMS

Phenylketonuria (PKU)
Metabolic Diseases
Skin diseases

ActoBio Therapeutics™ holds an intellectual property portfolio with over 250 granted patents and more than 50 pending patent applications covering clinical candidates across the technology platform.